查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1401178

抗血小板藥物市場 - 全球規模、佔有率、趨勢分析、機會、預測報告，2019-2029

Antiplatelet Drugs Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Drugs ; By Indication ; By Distribution Channel ; By Route of Administration ; By End Use ; By Region
出版日期: | 出版商: Blueweave Consulting | 英文 400 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023年至2029年，全球抗血小板藥物市場規模將以5.32%的複合年成長率成長，2029年將達到29.2億美元。

全球抗血小板藥物市場的促進因素包括心血管疾病盛行率的上升、人口高齡化的加劇、藥物開發技術的進步、預防醫學意識的增強以及血栓事件一級和二級預防需求的增加，市場蓬勃發展的原因是抗血小板藥物的需求迅速增加。

領先的策略諮詢和市場研究公司 BlueWeave Consulting 在最近的一項研究中估計，2022 年全球抗血小板藥物市場規模為 21.4 億美元。 2023-2029年預測期內，全球抗血小板藥物市場規模預計將以5.32%的複合年成長率成長，2029年將達到29.2億美元。全球抗血小板藥物市場的成長很大程度上是由全球心血管疾病和相關問題的增加所推動的。為了滿足每位患者的需求，製藥公司正在專注於開發更個體化的抗血小板藥物。市場上的研發活動正在迅速增加，這可能會導致新配方的開發和上市。抗血小板藥物在新興國家的使用也越來越多，刺激了市場的擴張。此外，患者依從性的提高和新的給藥技術也推動了市場擴張趨勢。

機會－增加醫療基礎建設投資

隨著全球醫療基礎設施投資大幅增加，全球抗血小板藥物市場已成為投資者利潤豐厚的領域。隨著對加強醫療設施的重視，對先進抗血小板療法的需求不斷增加。抓住機會為這一重要的醫療保健領域做出貢獻，並確保獲得在預防心血管事件方面發揮關鍵作用的創新抗血小板藥物。這個市場的快速成長不僅符合全球健康優先事項，而且還為那些隨著醫療保健進步而尋求永續回報的人提供了策略性投資工具。

COVID-19對全球抗血小板藥物市場的影響

隨著世界各地的醫療系統將重點轉移到對抗病毒上，COVID-19 大大流行對全球抗血小板藥物市場產生了重大影響。在大流行高峰期，選擇性治療被推遲，抗血小板藥物的處方和需求減少。供應鏈和製造中斷也導致暫時的供不應求和價格波動。然而，隨著人們越來越重視遠端醫療和門診護理，以確保患者繼續獲得所需的藥物，市場已顯示出彈性。隨著疫情消退，由於常規醫療服務的恢復和心血管健康意識的提高，全球抗血小板藥物市場預計將復甦。

全球抗血小板藥物市場－依適應症分類

依適應症，全球抗血小板藥物市場分為心肌梗塞、經皮冠狀動脈介入及動脈血栓症形成。心肌梗塞是全球抗血小板藥物市場中最大的部分。這部分包括心臟病發作的治療，這是一個具有全球重要性的健康問題。由於心血管疾病盛行率不斷增加，心肌梗塞患者對預防血液凝固的抗血小板藥物的需求仍然很高。雖然經皮冠狀動脈介入和動脈血栓症形成也是重要的細分領域，但心肌梗塞對整體市場收益和成長的貢獻最大，因為在這種特定疾病狀態下迫切需要有效和挽救生命的治療。

本報告的詳細分析提供了有關全球抗血小板藥物市場的成長潛力、未來趨勢和統計數據的資訊。它還重點關注推動市場總規模預測的因素。該報告致力於提供全球抗血小板藥物市場的最新技術趨勢以及產業見解，幫助決策者做出策略決策。此外，我們也分析市場成長動力、挑戰和競爭。

目錄

第1章 研究框架

第 2 章執行摘要

第3章 全球抗血小板藥物市場洞察

  • 產業價值鏈分析
  • DROC分析
    • 生長促進因子
      • 心臟病和遺傳性疾病的盛行率增加
      • 由於高齡化，對新型口服抗凝血藥物的需求不斷增加
    • 抑制因素
      • 嚴格的監理政策
      • 抗血栓藥物高成本且副作用大
    • 機會
      • 增加研發活動
      • 加大醫療基礎建設投資
    • 任務
      • 新興經濟體缺乏醫療保健基礎設施
      • 一些抗血小板藥物的安全性、有效性和耐受性的局限性
  • 科技進步/最新發展
  • 法律規範
  • 波特五力分析

第4章 全球抗血小板藥物市場概況

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 透過藥物
      • 阿斯匹靈
      • Clopidogrel
      • 奇卡古雷勒
      • 普拉格雷
      • 其他
    • 按指示
      • 心肌梗塞
      • 經皮冠狀動脈介入
      • 動脈血栓症
      • 其他
    • 按配銷通路
      • 醫院藥房
      • 零售藥房
      • 線上藥房
      • 其他
    • 依給藥途徑
      • 口服
      • 注射
    • 按最終用途
      • 醫院
      • 專科診所
      • 居家護理
      • 其他
    • 按地區
      • 北美洲
      • 歐洲
      • 亞太地區 (APAC)
      • 拉丁美洲 (LATAM)
      • 中東和非洲 (MEA)

第5章 北美抗血小板藥物市場

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 透過藥物
    • 按指示
    • 按配銷通路
    • 依給藥途徑
    • 按最終用途
    • 按國家/地區
      • 美國
      • 加拿大

第6章 歐洲抗血小板藥物市場

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 透過藥物
    • 按指示
    • 按配銷通路
    • 依給藥途徑
    • 按最終用途
    • 按國家/地區
      • 德國
      • 英國
      • 義大利
      • 法國
      • 西班牙
      • 比利時
      • 俄羅斯
      • 荷蘭
      • 其他

第7章亞太地區抗血小板藥物市場

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 透過藥物
    • 按指示
    • 按配銷通路
    • 依給藥途徑
    • 按最終用途
    • 按國家/地區
      • 中國
      • 印度
      • 日本
      • 韓國
      • 澳洲和紐西蘭
      • 印尼
      • 馬來西亞
      • 新加坡
      • 越南
      • 其他

第8章拉丁美洲抗血小板藥物市場

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 透過藥物
    • 按指示
    • 按配銷通路
    • 依給藥途徑
    • 按最終用途
    • 按國家/地區
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘魯
      • 其他

第9章中東和非洲抗血小板藥物市場

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 透過藥物
    • 按指示
    • 按配銷通路
    • 依給藥途徑
    • 按最終用途
    • 按國家/地區
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 科威特
      • 南非
      • 奈及利亞
      • 阿爾及利亞
      • 其他

第10章競爭形勢

  • 主要企業及其產品列表
  • 2022年全球抗血小板藥企業市場佔有率分析
  • 透過管理參數進行競爭基準化分析
  • 主要策略發展（合併、收購、合作夥伴關係等）

第11章 新型冠狀病毒感染疾病（COVID-19）對全球抗血小板藥物市場的影響

第12章 公司簡介（公司簡介、財務矩陣、競爭形勢、關鍵人力資源、主要競爭、聯絡地址、策略展望、SWOT分析）

  • Eli Lilly and Company
  • Pfizer Inc.
  • GSK Group of Companies（US）
  • Novartis AG
  • EnBiotix Inc.
  • Johnson &Johnson Private Limited
  • Merck &Co., Inc.
  • Alexion Pharmaceuticals, Inc.
  • Melinta Therapeutics, LLC
  • Vertex Pharmaceuticals Incorporated
  • AnaSpec
  • AMP Biotech
  • Phoenix Biotechnology Inc.
  • Novabiotics
  • Ontores Biotechnologies Inc.
  • 其他主要企業

第13章 主要戰略建議

第14章調查方法

簡介目錄
Product Code: BWC231048

Global Antiplatelet Drugs Market Size Grows at CAGR of 5.32% During 2023-2029 to Reach USD 2.92 Billion by 2029

Global antiplatelet drugs market is flourishing due to the increasing prevalence of cardiovascular diseases, the growing aging population, advancements in drug development technologies, growing awareness about preventive healthcare, and a surge in demand for antiplatelet drugs for primary and secondary prevention of thrombotic events.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the Global Antiplatelet Drugs Market size at USD 2.14 billion in 2022. During the forecast period between 2023 and 2029, the Global Antiplatelet Drugs Market size is to grow at a CAGR of 5.32% reaching a value of USD 2.92 billion by 2029. An increase in cardiovascular illnesses and associated problems worldwide are major factors behind the growth of the global market for antiplatelet medicines. To meet the demands of each patient specifically, pharmaceutical companies are concentrating on creating more sophisticated and individualized antiplatelet medicines. The market is witnessing a rapid increase in R&D activities, which could result in the development and launch of novel drug formulations. Antiplatelet medications are also being used more frequently in emerging economies, which is fueling market expansion. Also, improvements in patient compliance and new drug delivery techniques are adding to the market's upward trend.

Opportunity - Increasing Investments in Healthcare Infrastructure

As worldwide healthcare infrastructure experiences a significant upswing in investments, the Global Antiplatelet Drugs Market emerges as a lucrative sector for prospective investors. With a rising focus on enhancing medical facilities, there is a growing demand for advanced antiplatelet therapies. Seize the opportunity to contribute to this vital healthcare segment, ensuring access to innovative antiplatelet drugs that play a crucial role in preventing cardiovascular events. This market surge not only aligns with global health priorities but also presents a strategic investment avenue for those seeking sustainable returns in the flourishing landscape of healthcare advancements.

Impact of COVID-19 on Global Antiplatelet Drugs Market

The COVID-19 pandemic significantly impacted Global Antiplatelet Drugs Market, as healthcare systems worldwide shifted focus to combat the virus. During the peak of the pandemic, elective procedures were postponed, leading to reduced prescriptions and demand for antiplatelet drugs. Also, disruptions in the supply chain and manufacturing caused temporary shortages and price fluctuations. However, the market showed resilience with the increasing emphasis on telemedicine and outpatient care, ensuring continuous patient access to essential medications. As the pandemic abates, the Global Antiplatelet Drugs Market is expected to rebound, driven by the resumption of routine medical services and growing awareness of cardiovascular health.

Global Antiplatelet Drugs Market - By Indication

By indication, Global Antiplatelet Drugs Market is divided into Myocardial infarction, Percutaneous Coronary Interventions, and Arterial Thrombosis segments. Myocardial infarction is the largest segment in the Global Antiplatelet Drugs Market. The segment encompasses the treatment of heart attacks, which is a significant health concern worldwide. The demand for antiplatelet drugs to prevent blood clotting in patients suffering from myocardial infarction remains high due to the increasing prevalence of cardiovascular diseases. While percutaneous coronary interventions and arterial thrombosis are also important segments, myocardial infarction stands out as the most substantial contributor to the overall market revenue and growth, driven by the critical need for effective and life-saving treatments in this specific medical condition.

Competitive Landscape

Global Antiplatelet Drugs Market is fiercely competitive. Major companies in the market include Eli Lilly and Company, Pfizer Inc., GSK Group of Companies (U.S), Novartis AG, EnBiotix Inc., Johnson & Johnson Private Limited, Merck & Co., Inc., Alexion Pharmaceuticals, Inc., Melinta Therapeutics, LLC, Vertex Pharmaceuticals Incorporated, AnaSpec, AMP Biotech, Phoenix Biotechnology Inc., Novabiotics, and Ontores Biotechnologies Inc. These companies use various strategies, including increasing investments in their R&D activities, mergers, and acquisitions, joint ventures, collaborations, licensing agreements, and new product and service releases to further strengthen their position in Global Antiplatelet Drugs Market.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Antiplatelet Drugs Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Antiplatelet Drugs Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Drugs Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Antiplatelet Drugs Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Increase in the prevalence of cardiac and hereditary diseases
      • 3.2.1.2. Growing demand for novel oral anticoagulants coupled with the aging population
    • 3.2.2. Restraints
      • 3.2.2.1. Stringent regulatory policies
      • 3.2.2.2. High cost and side effects of antithrombotic drugs
    • 3.2.3. Opportunities
      • 3.2.3.1. Increase in the number of research and development activities
      • 3.2.3.2. Increasing investment in healthcare infrastructure
    • 3.2.4. Challenges
      • 3.2.4.1. Lack of healthcare infrastructure in developing economies
      • 3.2.4.2. Limitations in safety, efficacy, and tolerability of some antiplatelet drugs
  • 3.3. Technological Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Antiplatelet Drugs Market Overview

  • 4.1. Market Size & Forecast, 2019-2029
    • 4.1.1. By Value (USD Billion)
  • 4.2. Market Share & Forecast
    • 4.2.1. By Drugs
      • 4.2.1.1. Aspirin
      • 4.2.1.2. Clopidogrel
      • 4.2.1.3. Ticagrelor
      • 4.2.1.4. Prasugrel
      • 4.2.1.5. Others
    • 4.2.2. By Indication
      • 4.2.2.1. Myocardial Infraction
      • 4.2.2.2. Percutaneous Coronary Interventions
      • 4.2.2.3. Arterial Thrombosis
      • 4.2.2.4. Others
    • 4.2.3. By Distribution Channel
      • 4.2.3.1. Hospital Pharmacy
      • 4.2.3.2. Retail Pharmacy
      • 4.2.3.3. Online Pharmacy
      • 4.2.3.4. Others
    • 4.2.4. By Route of Administration
      • 4.2.4.1. Oral
      • 4.2.4.2. Injectable
    • 4.2.5. By End Use
      • 4.2.5.1. Hospitals
      • 4.2.5.2. Specialty Clinics
      • 4.2.5.3. Homecare
      • 4.2.5.4. Others
    • 4.2.6. By Region
      • 4.2.6.1. North America
      • 4.2.6.2. Europe
      • 4.2.6.3. Asia Pacific (APAC)
      • 4.2.6.4. Latin America (LATAM)
      • 4.2.6.5. Middle East and Africa (MEA)

5. North America Antiplatelet Drugs Market

  • 5.1. Market Size & Forecast, 2019-2029
    • 5.1.1. By Value (USD Million)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drugs
    • 5.2.2. By Indication
    • 5.2.3. By Distribution Channel
    • 5.2.4. By Route of Administration
    • 5.2.5. By End Use
    • 5.2.6. By Country
      • 5.2.6.1. United States
      • 5.2.6.1.1. By Drugs
      • 5.2.6.1.2. By Indication
      • 5.2.6.1.3. By Distribution Channel
      • 5.2.6.1.4. By Route of Administration
      • 5.2.6.1.5. By End Use
      • 5.2.6.2. Canada
      • 5.2.6.2.1. By Drugs
      • 5.2.6.2.2. By Indication
      • 5.2.6.2.3. By Distribution Channel
      • 5.2.6.2.4. By Route of Administration
      • 5.2.6.2.5. By End Use

6. Europe Antiplatelet Drugs Market

  • 6.1. Market Size & Forecast, 2019-2029
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drugs
    • 6.2.2. By Indication
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Route of Administration
    • 6.2.5. By End Use
    • 6.2.6. By Country
      • 6.2.6.1. Germany
      • 6.2.6.1.1. By Drugs
      • 6.2.6.1.2. By Indication
      • 6.2.6.1.3. By Distribution Channel
      • 6.2.6.1.4. By Route of Administration
      • 6.2.6.1.5. By End Use
      • 6.2.6.2. United Kingdom
      • 6.2.6.2.1. By Drugs
      • 6.2.6.2.2. By Indication
      • 6.2.6.2.3. By Distribution Channel
      • 6.2.6.2.4. By Route of Administration
      • 6.2.6.2.5. By End Use
      • 6.2.6.3. Italy
      • 6.2.6.3.1. By Drugs
      • 6.2.6.3.2. By Indication
      • 6.2.6.3.3. By Distribution Channel
      • 6.2.6.3.4. By Route of Administration
      • 6.2.6.3.5. By End Use
      • 6.2.6.4. France
      • 6.2.6.4.1. By Drugs
      • 6.2.6.4.2. By Indication
      • 6.2.6.4.3. By Distribution Channel
      • 6.2.6.4.4. By Route of Administration
      • 6.2.6.4.5. By End Use
      • 6.2.6.5. Spain
      • 6.2.6.5.1. By Drugs
      • 6.2.6.5.2. By Indication
      • 6.2.6.5.3. By Distribution Channel
      • 6.2.6.5.4. By Route of Administration
      • 6.2.6.5.5. By End Use
      • 6.2.6.6. Belgium
      • 6.2.6.6.1. By Drugs
      • 6.2.6.6.2. By Indication
      • 6.2.6.6.3. By Distribution Channel
      • 6.2.6.6.4. By Route of Administration
      • 6.2.6.6.5. By End Use
      • 6.2.6.7. Russia
      • 6.2.6.7.1. By Drugs
      • 6.2.6.7.2. By Indication
      • 6.2.6.7.3. By Distribution Channel
      • 6.2.6.7.4. By Route of Administration
      • 6.2.6.7.5. By End Use
      • 6.2.6.8. The Netherlands
      • 6.2.6.8.1. By Drugs
      • 6.2.6.8.2. By Indication
      • 6.2.6.8.3. By Distribution Channel
      • 6.2.6.8.4. By Route of Administration
      • 6.2.6.8.5. By End Use
      • 6.2.6.9. Rest of Europe
      • 6.2.6.9.1. By Drugs
      • 6.2.6.9.2. By Indication
      • 6.2.6.9.3. By Distribution Channel
      • 6.2.6.9.4. By Route of Administration
      • 6.2.6.9.5. By End Use

7. Asia Pacific Antiplatelet Drugs Market

  • 7.1. Market Size & Forecast, 2019-2029
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drugs
    • 7.2.2. By Indication
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Route of Administration
    • 7.2.5. By End Use
    • 7.2.6. By Country
      • 7.2.6.1. China
      • 7.2.6.1.1. By Drugs
      • 7.2.6.1.2. By Indication
      • 7.2.6.1.3. By Distribution Channel
      • 7.2.6.1.4. By Route of Administration
      • 7.2.6.1.5. By End Use
      • 7.2.6.2. India
      • 7.2.6.2.1. By Drugs
      • 7.2.6.2.2. By Indication
      • 7.2.6.2.3. By Distribution Channel
      • 7.2.6.2.4. By Route of Administration
      • 7.2.6.2.5. By End Use
      • 7.2.6.3. Japan
      • 7.2.6.3.1. By Drugs
      • 7.2.6.3.2. By Indication
      • 7.2.6.3.3. By Distribution Channel
      • 7.2.6.3.4. By Route of Administration
      • 7.2.6.3.5. By End Use
      • 7.2.6.4. South Korea
      • 7.2.6.4.1. By Drugs
      • 7.2.6.4.2. By Indication
      • 7.2.6.4.3. By Distribution Channel
      • 7.2.6.4.4. By Route of Administration
      • 7.2.6.4.5. By End Use
      • 7.2.6.5. Australia & New Zealand
      • 7.2.6.5.1. By Drugs
      • 7.2.6.5.2. By Indication
      • 7.2.6.5.3. By Distribution Channel
      • 7.2.6.5.4. By Route of Administration
      • 7.2.6.5.5. By End Use
      • 7.2.6.6. Indonesia
      • 7.2.6.6.1. By Drugs
      • 7.2.6.6.2. By Indication
      • 7.2.6.6.3. By Distribution Channel
      • 7.2.6.6.4. By Route of Administration
      • 7.2.6.6.5. By End Use
      • 7.2.6.7. Malaysia
      • 7.2.6.7.1. By Drugs
      • 7.2.6.7.2. By Indication
      • 7.2.6.7.3. By Distribution Channel
      • 7.2.6.7.4. By Route of Administration
      • 7.2.6.7.5. By End Use
      • 7.2.6.8. Singapore
      • 7.2.6.8.1. By Drugs
      • 7.2.6.8.2. By Indication
      • 7.2.6.8.3. By Distribution Channel
      • 7.2.6.8.4. By Route of Administration
      • 7.2.6.8.5. By End Use
      • 7.2.6.9. Vietnam
      • 7.2.6.9.1. By Drugs
      • 7.2.6.9.2. By Indication
      • 7.2.6.9.3. By Distribution Channel
      • 7.2.6.9.4. By Route of Administration
      • 7.2.6.9.5. By End Use
      • 7.2.6.10. Rest of APAC
      • 7.2.6.10.1. By Drugs
      • 7.2.6.10.2. By Indication
      • 7.2.6.10.3. By Distribution Channel
      • 7.2.6.10.4. By Route of Administration
      • 7.2.6.10.5. By End Use

8. Latin America Antiplatelet Drugs Market

  • 8.1. Market Size & Forecast, 2019-2029
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drugs
    • 8.2.2. By Indication
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Route of Administration
    • 8.2.5. By End Use
    • 8.2.6. By Country
      • 8.2.6.1. Brazil
      • 8.2.6.1.1. By Drugs
      • 8.2.6.1.2. By Indication
      • 8.2.6.1.3. By Distribution Channel
      • 8.2.6.1.4. By Route of Administration
      • 8.2.6.1.5. By End Use
      • 8.2.6.2. Mexico
      • 8.2.6.2.1. By Drugs
      • 8.2.6.2.2. By Indication
      • 8.2.6.2.3. By Distribution Channel
      • 8.2.6.2.4. By Route of Administration
      • 8.2.6.2.5. By End Use
      • 8.2.6.3. Argentina
      • 8.2.6.3.1. By Drugs
      • 8.2.6.3.2. By Indication
      • 8.2.6.3.3. By Distribution Channel
      • 8.2.6.3.4. By Route of Administration
      • 8.2.6.3.5. By End Use
      • 8.2.6.4. Peru
      • 8.2.6.4.1. By Drugs
      • 8.2.6.4.2. By Indication
      • 8.2.6.4.3. By Distribution Channel
      • 8.2.6.4.4. By Route of Administration
      • 8.2.6.4.5. By End Use
      • 8.2.6.5. Rest of LATAM
      • 8.2.6.5.1. By Drugs
      • 8.2.6.5.2. By Indication
      • 8.2.6.5.3. By Distribution Channel
      • 8.2.6.5.4. By Route of Administration
      • 8.2.6.5.5. By End Use

9. Middle East and Africa Antiplatelet Drugs Market

  • 9.1. Market Size & Forecast, 2019-2029
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drugs
    • 9.2.2. By Indication
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Route of Administration
    • 9.2.5. By End Use
    • 9.2.6. By Country
      • 9.2.6.1. Saudi Arabia
      • 9.2.6.1.1. By Drugs
      • 9.2.6.1.2. By Indication
      • 9.2.6.1.3. By Distribution Channel
      • 9.2.6.1.4. By Route of Administration
      • 9.2.6.1.5. By End Use
      • 9.2.6.2. UAE
      • 9.2.6.2.1. By Drugs
      • 9.2.6.2.2. By Indication
      • 9.2.6.2.3. By Distribution Channel
      • 9.2.6.2.4. By Route of Administration
      • 9.2.6.2.5. By End Use
      • 9.2.6.3. Qatar
      • 9.2.6.3.1. By Drugs
      • 9.2.6.3.2. By Indication
      • 9.2.6.3.3. By Distribution Channel
      • 9.2.6.3.4. By Route of Administration
      • 9.2.6.3.5. By End Use
      • 9.2.6.4. Kuwait
      • 9.2.6.4.1. By Drugs
      • 9.2.6.4.2. By Indication
      • 9.2.6.4.3. By Distribution Channel
      • 9.2.6.4.4. By Route of Administration
      • 9.2.6.4.5. By End Use
      • 9.2.6.5. South Africa
      • 9.2.6.5.1. By Drugs
      • 9.2.6.5.2. By Indication
      • 9.2.6.5.3. By Distribution Channel
      • 9.2.6.5.4. By Route of Administration
      • 9.2.6.5.5. By End Use
      • 9.2.6.6. Nigeria
      • 9.2.6.6.1. By Drugs
      • 9.2.6.6.2. By Indication
      • 9.2.6.6.3. By Distribution Channel
      • 9.2.6.6.4. By Route of Administration
      • 9.2.6.6.5. By End Use
      • 9.2.6.7. Algeria
      • 9.2.6.7.1. By Drugs
      • 9.2.6.7.2. By Indication
      • 9.2.6.7.3. By Distribution Channel
      • 9.2.6.7.4. By Route of Administration
      • 9.2.6.7.5. By End Use
      • 9.2.6.8. Rest of MEA
      • 9.2.6.8.1. By Drugs
      • 9.2.6.8.2. By Indication
      • 9.2.6.8.3. By Distribution Channel
      • 9.2.6.8.4. By Route of Administration
      • 9.2.6.8.5. By End Use

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Antiplatelet Drugs Company Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of COVID-19 on Global Antiplatelet Drugs Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

  • 12.1. Eli Lilly and Company
  • 12.2. Pfizer Inc.
  • 12.3. GSK Group of Companies (U.S)
  • 12.4. Novartis AG
  • 12.5. EnBiotix Inc.
  • 12.6. Johnson & Johnson Private Limited
  • 12.7. Merck & Co., Inc.
  • 12.8. Alexion Pharmaceuticals, Inc.
  • 12.9. Melinta Therapeutics, LLC
  • 12.10. Vertex Pharmaceuticals Incorporated
  • 12.11. AnaSpec
  • 12.12. AMP Biotech
  • 12.13. Phoenix Biotechnology Inc.
  • 12.14. Novabiotics
  • 12.15. Ontores Biotechnologies Inc.
  • 12.16. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents, By Region
  • 14.5. Assumptions & Limitations